Cellares and TScan Therapeutics agreed to evaluate automated manufacturing for TSC-101, TScan’s TCR-T therapy candidate aimed at residual disease and relapse prevention in acute myeloid leukemia and myelodysplastic syndromes following allogeneic hematopoietic cell transplantation. The partnership centers on Cellares’ Cell Shuttle end-to-end automated manufacturing platform and Cell Q automated quality control and release testing system. Both are intended to run as closed systems, reducing process variability, labor intensity, and capacity constraints across geographies. TScan plans to begin a pivotal trial in the second quarter of 2026, and the evaluation is positioned as a commercial readiness step ahead of scaling. The companies say automation could improve consistency for a manufacturing-intensive therapy type where variability can affect product performance. For the sector, this is another move to de-risk scale-up and accelerate the shift from manual cell therapy production toward standardized platforms capable of supporting broader patient access.